Glycyx MOR, Inc.

Funding and NIH signals

• NIH award NIH awarded $1.05M (SBIR Phase II 5R44CA306565-02, continuation, notice Sep 14, 2026). NIH RePORTER 5R44CA306565-02 (Sep 14, 2026)
  Evidence (1 event)

  • Sep 14, 2026 · NIH RePORTER 5R44CA306565-02
    Organization: GLYCYX MOR, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44CA306565-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1047803; Administering IC: National Cancer Institute; Project title: A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1); Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals